VistaGen Therapeutics, Inc. (VTGN)
| Market Cap | 359.46M |
| Revenue (ttm) | 1.47M |
| Net Income (ttm) | -56.49M |
| Shares Out | 215.25M |
| EPS (ttm) | -0.37 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,228,263 |
| Open | 1.80 |
| Previous Close | 1.80 |
| Day's Range | 1.66 - 1.81 |
| 52-Week Range | 0.72 - 3.55 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 7.33 (+338.9%) |
| Earnings Date | Nov 10, 2021 |
About VTGN
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment diso...
Financial Performance
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VTGN stock is "Strong Buy." The 12-month stock price forecast is 7.33, which is an increase of 338.92% from the latest price.
News
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the...
VistaGen Therapeutics Reports Fiscal Year 2022 Second Quarter Financial Results and Provides Corporate Update
PALISADE Phase 3 clinical trials of PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan
Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VistaGen Therapeutics Expands Clinical Development of PH94B with Initiation of Phase 2A Trial in Adjustment Disorder
Study Launches Phase 2A Clinical Program Designed to Explore PH94B's Potential in Multiple Additional Anxiety Disorders
VistaGen Therapeutics Reports New Preclinical Mechanism of Action Data Supporting PH94B's Potential Anti-Anxiety Acti...
Preclinical study of intranasal radiolabeled PH94B in laboratory rats further differentiates PH94B's mechanism of action from benzodiazepines Preclinical study of intranasal radiolabeled PH94B in labora...
VistaGen Therapeutics Further Advances PALISADE Phase 3 Program for PH94B in Social Anxiety Disorder with Initiation ...
PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder PALISADE Phase 3 Program focused on PH94B's potential as a rapid...
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: VistaGen Therapeutics Q1 Earnings
Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the past year to ($0.04), ...
VistaGen Therapeutics Reports Fiscal Year 2022 First Quarter Financial Results and Provides Corporate Update
PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan
VistaGen Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential ...
VistaGen Therapeutics to Participate in William Blair Biotech Focus Conference 2021
SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential ...
VistaGen Therapeutics Announces Appointment of Mary L. Rotunno to its Board of Directors
Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rotun...
Why VistaGen Therapeutics Stock Jumped Today
Investors liked the drugmaker's corporate update.
VistaGen Therapeutics: Q4 Earnings Insights
Shares of VistaGen Therapeutics (NASDAQ:VTGN) decreased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 328.57% over the past year to ($0.30...
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
PALISADE-1 Phase 3 trial underway to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD)
8 Penny Stocks to Watch Right Now As June Comes to an End
Which penny stocks are investors watching as June comes to an end? The post 8 Penny Stocks to Watch Right Now As June Comes to an End appeared first on Penny Stocks to Buy, Picks, News and Information |...
VistaGen Therapeutics to Report 2021 Fiscal Year End Financial Results, Provide a Business Update and Host Conference...
SOUTH SAN FRANCISCO, Calif., June 25, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the pot...
Sage Stock Declines on Late-Stage Depression Study Data
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
VistaGen Therapeutics Set to Join the Russell 2000® Index
SOUTH SAN FRANCISCO, Calif., June 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of me...
7 A-Rated Biotech Stocks to Buy Now
Investors in search of long-term growth are increasingly choosing biotech stocks like BNTX stock and MRNA stock for their portfolios. The post 7 A-Rated Biotech Stocks to Buy Now appeared first on Inves...
5 Buy-Rated Stocks Trading Below $10 With Outstanding Upside Potential
While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.
VistaGen Kick Starts Late-Stage Social Anxiety Disorder Study with PH94B
VistaGen Therapeutics Inc (NASDAQ: VTGN) has initiated its PALISADE Phase 3 study to evaluate PH94B for the acute treatment of Social Anxiety Disorder (SAD). PH94B is an odorless, rapid-onset, investiga...
5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now
Analysts say these are penny stocks to buy right now & have bullish targets to back it up. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 219% Right Now appeared first on Penny Stocks to...